Skip to main content

Table 1 Drug-pathway association in the DTPN of Luminal A subtype

From: In silico identification of drug target pathways in breast cancer subtypes using pathway cross-talk inhibition

Drug Pathway nNE and PCI (vs NE = 0.3218)
Capecitabine Eicosanoid 0.3194 (PCI 0.75%)
Fulvestrant Bladder cancer signaling (1); estrogen receptor (2); regulation of cellular mechanics by calpain protease (3) (1) 0.3179 (PCI 1.18%)
(2) 0.3137 (PCI 2.50%)
(3) 0.3198 (PCI 0.59%)
(1–2) 0.3094 (PCI 3.84%)
(1–3) 0.3159 (PCI 1.81%)
(2–3) 0.3115 (PCI 3.18%)
(1–2–3) 0.3071 (PCI 4.56%)
Gemcitabine Regulation of cellular mechanics by calpain protease 0.3198 (PCI 0.59%)
Methotrexate FXR/RXR activation 0.3193 (PCI 0.75%)
Raloxifene Estrogen receptor (1); RAR activation (2) (1) 0.3137 (PCI 2.50%)
(2) 0.3170 (PCI 1.47%)
(1–2) 0.3098 (PCI 3.70%)
Tamoxifen Estrogen receptor (1); factors promoting cardiogenesis in vertebrates (2); human embryonic stem cell pluripotency (3); RAR activation (4) (1) 0.3137 (PCI 2.50%)
(2) 0.3180 (PCI 1.17%)
(3) 0.3157 (PCI 1.86%)
(4) 0.3170 (PCI 1.47%)
(1–2) 0.3092 (PCI 3.88%)
(1–3) 0.3071 (PCI 4.56%)
(1–4) 0.3098 (PCI 3.70%)
(2–3) 0.3098 (PCI 3.70%)
(2–4) 0.3129 (PCI 2.74%)
(3–4) 0.3103 (PCI 3.56%)
(1–2–3) 0.3003 (PCI 6.68%)
(2–3–4) 0.3025 (PCI 5.98%)
(3–4–1) 0.3051 (PCI 5.18%)
(1–2–3–4) 0.2941 (PCI 8.59%)
Toremifene FXR/RXR activation (1); pregnenolone biosynthesis (2) (1) 0.3193 (PCI 0.75%)
(2) 0.3192 (PCI 0.79%)
(1–2) 0.3165 (PCI 1.61%)
Vinblastine Axonal guidance signaling (1); FXR/RXR activation (2) (1) 0.3216 (PCI 0.05%)
(2) 0.3193 (PCI 0.75%)
(1–2) 0.3190 (PCI 0.86%)